Development of Human Anti-Influenza Monoclonal Antibodies for Treatment of Flu

Janessen Vaccines And Prevention, Bv, Leiden

Investigators

Abstract

The overall objectives and scope of this contract is to advance the development of human monoclonal antibody (mAbs) products for treatment of Influenza A viral infections. The scope of work for this contract includes nonclinical, preclinical, and clinical development activities.